The Evolving Clinical Role of Actinium-225 and Bismuth-213 for Targeted Alpha Therapy (TAT) - Production, Radiopharmaceutical Development and Clinical Applications

Valery       Radchenko; Paul       Schaffer; F.F. (Russ)      Knapp

doi:10.2174/187447101103180911115600

Volume 11, Issue 3, 2018

Page: [154 - 155] Pages: 2

DOI: 10.2174/187447101103180911115600

« Previous Next »

Rights & Permissions Print Cite

Article Metrics

Journal Information

About Journal
Editorial Board
Current Issue
Volumes /Issues

For Authors

Author Guidelines
Graphical Abstracts
Fabricating and Stating False Information
Research Misconduct
Post Publication Discussions and Corrections
Publishing Ethics and Rectitude
Increase Visibility of Your Article
Archiving Policies
Peer Review Workflow
Order Your Article Before Print
Promote Your Article
Manuscript Transfer Facility
Editorial Policies
Allegations from Whistleblowers

For Editors

Guest Editor Guidelines
Editorial Management
Fabricating and Stating False Information
Publishing Ethics and Rectitude
Ethical Guidelines for New Editors
Peer Review Workflow

For Reviewers

Reviewer Guidelines
Peer Review Workflow
Fabricating and Stating False Information
Publishing Ethics and Rectitude

Explore Articles

Abstract Ahead of Print 0
Early View 8
Free Online Copy
Most Cited Articles
Most Accessed Articles
Editor's Choice
Thematic Issues

Open Access

Open Access Articles

For Visitors

Library Recommendation
Trial Requests
Advertise with Us
Meet the Executive Guest Editor(s)
Brand Ambassador
Author's Comment & Reviews
New Journals 2023
New Journals 2024
Alert Subscription
TOC Alert

DOI https://dx.doi.org/10.2174/187447101103180911115600	Print ISSN 1874-4710
Publisher Name Bentham Science Publisher	Online ISSN 1874-4729

Current Radiopharmaceuticals

The Evolving Clinical Role of Actinium-225 and Bismuth-213 for Targeted Alpha Therapy (TAT) - Production, Radiopharmaceutical Development and Clinical Applications

Related Journals

Related Books